Mostrar el registro sencillo del ítem
dc.contributor.author | Padhya, D. P. | |
dc.contributor.author | Prutsky, G. J. | |
dc.contributor.author | Nemergut, M. E. | |
dc.contributor.author | Schears, G. S. | |
dc.contributor.author | Flick, R. P. | |
dc.contributor.author | Farah, W. | |
dc.contributor.author | Wang, Z. | |
dc.contributor.author | Prokop, L. J. | |
dc.contributor.author | Murad, M. H. | |
dc.contributor.author | Alsawas, M. | |
dc.date.accessioned | 2019-07-04T17:00:23Z | |
dc.date.available | 2019-07-04T17:00:23Z | |
dc.date.issued | 2019 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/6898 | |
dc.description.abstract | OBJECTIVE: Specific protocols for anticoagulation for children on ECMO vary across institutions, with most using a continuous infusion of unfractionated heparin. The goal of this study is to aid clinician's decision on the best measure of heparin anticoagulation test; which would be the one that correlates well with heparin activity and helps in predicting hemorrhagic and thrombotic complications. DATA SOURCES: A comprehensive search of MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Scopus was conducted from each database's inception to 07/13/2018. STUDY SELECTION: Studies evaluating children (<18years) treated with ECMO and evaluating ACT, aPTT, TEG and Anti-Xa in any language were included. DATA EXTRACTION: Two reviewers selected and appraised studies independently, and abstracted data. RESULTS: We included 19 studies (759 patients, mean age 19.8months). Meta-analysis showed strong correlation between heparin dosing and anti-Xa. Additionally, there was not a strong correlation between laboratory tests and complications (hemorrhagic and thrombosis), or mortality. CONCLUSION: Based on current evidence, Anti-Xa is the only laboratory test that shows strong correlation with heparin infusion dose and seems like the most suitable test for monitoring of anticoagulation with heparin in children on ECMO. | en_US |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartofseries | Thrombosis Research | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | activated partial thromboplastin time | en_US |
dc.subject | anticoagulation | en_US |
dc.subject | Anticoagulation | en_US |
dc.subject | bleeding | en_US |
dc.subject | blood clotting factor 10a inhibitor | en_US |
dc.subject | blood clotting test | en_US |
dc.subject | child | en_US |
dc.subject | Complications | en_US |
dc.subject | Extracorporeal membrane oxygenation | en_US |
dc.subject | extracorporeal oxygenation | en_US |
dc.subject | heparin | en_US |
dc.subject | human | en_US |
dc.subject | Laboratory measures | en_US |
dc.subject | major clinical study | en_US |
dc.subject | meta analysis | en_US |
dc.subject | mortality | en_US |
dc.subject | Pediatrics | en_US |
dc.subject | priority journal | en_US |
dc.subject | Review | en_US |
dc.subject | systematic review | en_US |
dc.subject | thromboelastography | en_US |
dc.subject | thrombosis | en_US |
dc.title | Routine laboratory measures of heparin anticoagulation for children on extracorporeal membrane oxygenation: Systematic review and meta-analysis. | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1016/j.thromres.2019.05.006 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.02.06 | |
dc.relation.issn | 1879-2472 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |